BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On March 29, 2018, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Holdings Announces Publication in The Lancet Haematology.” A copy of such press release is attached hereto as Exhibit 99.1.

BIO-PATH HOLDINGS INC Exhibit
EX-99.1 2 tv489882_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1     Bio-Path Holdings Announces Publication in The Lancet Haematology   Prexigebersen was well tolerated and showed early anti-leukemic activity in combination with cytarabine in relapsed or refractory hematologic malignancies   HOUSTON—March 29,…
To view the full exhibit click here

About BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH)

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.